Valion Bio, Inc.
VBIONASDAQHealthcareBiotechnology
Previous close
$0.1226
+$0.0005 · +0.41%
VBIO company overview
Regular session · ET · Market data may be delayed.
Company profile
Company websiteValion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Michael R. Cavanaugh
- Listed since
- Nov 11, 2021
- Employees
- 52
Market position
Day range
Current $0.1226
52-week range
Current $0.1226
- Open
- $0.1166
- Previous close
- $0.1221
- Volume
- 3.91M
- 7.76× average
- Average volume
- 503.19K
- Average daily volume
- Market cap
- 507.74K USD
- Beta
- 1.86
- Market reference 1
- 50-day average
- $0.3902
- -68.58% below average
- 200-day average
- $1.0314
- -88.11% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -783.12K USD
- P/E (TTM)
- -2.45×
- P/B (TTM)
- 0.65×
- P/S (TTM)
- 0.27×
- EV / EBITDA
- 1.02×
- Earnings yield
- 0.00%
- Free cash flow yield
- 0.00%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 48.61%
- Operating margin
- -425.35%
- Net margin
- -229.23%
- Return on equity
- 0.00%
- Return on assets
- 0.00%
- Return on invested capital
- 0.00%
Financial health
- Debt / equity
- 0.02×
- Current ratio
- 0.57×
- Altman Z-score
- -0.54
- Piotroski F-score
- 3 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | 382K USD | — | — | — | 102.42K USD |
| Cost of goods sold | 350K USD | — | — | — | 77.94K USD |
| Gross profit | 32K USD | — | — | — | 24.48K USD |
| Research and development | — | 408.91K USD | 1.01M USD | 1.74M USD | 1.9M USD |
| Selling, general, and administrative | 800K USD | 1.93M USD | 2.68M USD | 2.82M USD | 2.52M USD |
| Operating expenses | 800K USD | 2.34M USD | 3.69M USD | 5.94M USD | 4.42M USD |
| Interest income | — | — | 1.25K USD | — | — |
| Interest expense | — | — | — | 6.78K USD | — |
| Depreciation and amortization | — | 1.46M USD | — | 12.27K USD | 87.75K USD |
| Operating income | −768K USD | −2.34M USD | −3.69M USD | −4.57M USD | −4.4M USD |
| Net income | — | −880.85K USD | −4.37M USD | −20.14M USD | −4.31M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 80%
- 4 beats, 0 misses, 1 met estimate
- Average EPS surprise
- +72.01%
- 5 comparable reports
- Latest EPS result
- -2.17
- Estimate -408 · Beat by 99.47%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
VBIO news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 20, 2016 | 1:10 | — | — |
Effective Jul 20, 2016
1:10
VBIO peers
Continue in GoAI
Research VBIOresearch.disclaimer